NOD2 and influenza: More recently, novel adjuvants and muramyl peptide derivatives targeting NOD2 have shown great potential at further increasing the immunogenicity of current vaccine constructs, including BCG, the nanoparticulate HIV-1 p24 vaccine, and the influenza subunit vaccine, among others27–29.